EP2262487A2 - Im mund zerfallende cilostazol-tablette - Google Patents

Im mund zerfallende cilostazol-tablette

Info

Publication number
EP2262487A2
EP2262487A2 EP09714454A EP09714454A EP2262487A2 EP 2262487 A2 EP2262487 A2 EP 2262487A2 EP 09714454 A EP09714454 A EP 09714454A EP 09714454 A EP09714454 A EP 09714454A EP 2262487 A2 EP2262487 A2 EP 2262487A2
Authority
EP
European Patent Office
Prior art keywords
orally disintegrating
disintegrating tablet
weight
parts
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09714454A
Other languages
English (en)
French (fr)
Inventor
Hidekazu Okazaki
Naoki Kamada
Masafumi Toda
Tadashi Fukami
Haruka Koizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP2262487A2 publication Critical patent/EP2262487A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to an oral tablet comprising cilostazol which can be disintegrated in oral cavity.
  • Cilostazol is 6- [4- (l-cyclohexyl-lH-tetrazol-5- yl)butoxy] -3, 4-dihydrocarbostyril as shown in the following formula (1), which exhibits high inhibitory action for platelet aggregation as well as inhibitory action for phosphodiesterase, antiulcer activity, hypotensive action, antiphlogistic action, etc. and thereby is widely used in clinical use as a drug for treating various ischemic symptoms caused by chronic arterial occlusion.
  • cilostazol has been additionally approved as a medicament having an indication which prevents the relapse after treatment of cerebral infarction (except cardiogenic cerebral infarction) (JP-A-56 (1981) -49378) .
  • the cilostazol tablets which are called Pletaal tablet 50 ® , Pletaal tablet 100 ® , Pletaal powder 20 % (OTSUKA PHARMACEUTICAL CO., LTD.) have already been on sale.
  • the present inventors had extensively studied a variety of formulations of cilostazol preparations which are possible to be taken without water previously, and have found that a powder formulation thereof wherein mannitol is formulated could be an orally disintegrable formulation (WO 2007/001086) .
  • a powder formulation or a particle formulation has some problems such as a difficult handling at the administration and an adhesion in oral cavity, and thus such formulation does not always satisfy elderly patients or patient suffering from swallowing disorder.
  • JP-B-3841804, WO 2005/037254, and WO 2005/037319 disclose compositions comprising saccharide (s) , disintegrating agent (s) and inorganic excipient(s) in a certain proportion, which are suitable for the manufacture of orally disintegrable tablets.
  • WO 2007/029376 discloses that such compositions can be improved by further adding lubricant (s) , disintegrating agent (s), and binder (s) to prepare more useful orally- disintegrable tablets.
  • lubricant s
  • disintegrating agent disintegrating agent
  • binder binder
  • each excipient contained in vehicle compositions of these orally disintegrable tablets had a widely broad range of choices and further the contents thereof were defined only by means of a certain range. It was unclear if a useful orally-disintegrable tablet of cilostazol could be prepared using the disclosed compositions, or if it was possible to select excipients suitable for an orally-disintegrable tablet of cilostazol from a widely broad range of excipients. Therefore, it was necessary for a skilled person to do extremely many experiments to find a useful orally-disintegrable tablet of cilostazol, and thus it was not thought that it was so easy to find a composition suitable for such tablet from the broad range.
  • the present inventors have extensively studied in order to solve the above-mentioned problems, and have found that it is possible to prepare a useful orally- disintegrating tablet of cilostazol using the composition described in WO 2007/029376; and furthermore a specifically limited range selected from the range of the excipients and the content proportions thereof described in 2007/029376 makes it possible to prepare an orally disintegrating tablet of cilostazol having more useful advantages about the disintegrability in oral cavity, formulating property and manufacturing process. Based upon the new findings, the present invention has been completed.
  • the present invention relates to the following inventions .
  • the present invention provides an orally disintegrating tablet comprising cilostazol and granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, which exhibits a good disintegrability in the oral cavity and a pleasant feeling in a mouth when administered and also has a sufficient hardness.
  • the present invention provides an orally disintegrating tablet comprising cilostazol, granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, and a glidant. Additionally, the present invention provides the orally disintegrating tablet which further comprises an organic excipient.
  • the present invention provides an orally disintegrating tablet comprising cilostazol, granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, a glidant, and an organic excipient, which may further optionally comprise one or more kinds of additives selected from the group consisting of lubricants, sweeteners, flavoring substances, flavors, binders and colorants .
  • the present invention provides an orally disintegrating tablet prepared by
  • a preferable composition of the orally disintegrating agent comprises
  • composition which is prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles of saccharides formed with mannitol and xylitol through a spray drying method, wherein
  • the saccharides comprising the combination of mannitol and xylitol are contained in 40 - 90 parts by weight;
  • the inorganic excipient is contained in 1 - 30 parts by weight;
  • the disintegrating agent is contained in 5 - 40 parts by weight, provided that the total amount of ingredients (a) , (b) and (c) is contained in 100 parts by weight, and the ratio of mannitol and xylitol by weight is 98 : 2 - 67 : 33, and
  • the starches are one or more kinds of starches selected from the group consisting of corn starch, rice starch, potato starch, partial pregelatinized starch, and hydroxypropyl starch;
  • the celluloses are one or more kinds of celluloses selected from the group consisting of crystalline cellulose, and carboxymethylcellulose .
  • the starches are corn starch, and the celluloses are crystalline cellulose.
  • more preferable glidant is one or more selected from the group consisting of hydrous silicon dioxide, light anhydrous silicic acid, and heavy anhydrous silicic acid, and the most preferably, hydrous silicon dioxide, and/or light anhydrous silicic acid.
  • the present invention provides an orally disintegrating tablet which is possible to be rapidly disintegrated in oral cavity, exhibits a pleasant feeling in a mouth when administered and also has a sufficient hardness, to many patients to whom cilostazol tablets are applied, especially aged patients and patients suffering from dysphagia.
  • the present invention provides an orally disintegrating tablet of cilostazol, which is possible to be rapidly disintegrated in oral cavity, and exhibits a pleasant feeling in a mouth when administered and also an identical dissolution property with the commercial cilostazol tablet.
  • the orally disintegrating tablet means a tablet prepared by adding particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, to cilostazol; especially, an orally disintegrating tablet prepared by adding to cilostazol, (i) particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, (ii) a glidant and (iii) an organic excipient.
  • Cilostazol can be prepared, for example, by the method described in JP-A-56 (1981) -49378.
  • the "granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides" (hereinafter referred to "granulated particles") used herein can be prepared by dispersing mannitol and a saccharide other than mannitol, a disintegrating agent, an inorganic substance in water and then spray-drying it.
  • a composition for the orally disintegrating tablet which can be prepared by the method described in WO 2005/037254 or WO 2005/037319.
  • the "two or more kinds of saccharides” contained in the granulated particles are a combination of mannitol and a saccharide which is not mannitol.
  • the saccharide means a sugar or a sugar alcohol.
  • the saccharide other than mannitol includes, for example, one or more selected from the group consisting of xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, Palatinit ® , Palatinose ® and the like.
  • the saccharide is a combination of mannitol and xylitol.
  • the "inorganic substance" contained in the granulated particles is preferred to be a pharmaceutically acceptable inorganic acid compound comprising any one or more of aluminum, magnesium and calcium. It includes at least one ingredients selected from, for example, magnesium aluminometasilicate, magnesium aluminosilicate, calcium hydrogenphosphate, calcium hydrogenphosphate anhydride, calcium hydrogenphosphate anhydride granule, hydrotalcite, aluminum silicate, calcium phosphate, calcium carbonate, calcium silicate, magnesium silicate, magnesium oxide, magnesium hydroxide, alumina-magnesium hydroxide, dry aluminum hydroxide gel, magnesium carbonate, etc.
  • the mean particle size of the inorganic substance is 0.1 - 100 urn, preferably 1 - 60 urn, and more preferably 1 - 40 urn. It is possible to use an inorganic substance milled by a conventional method in order to obtain the desired mean particle size.
  • the "disintegrating agent" contained in the granulated particles is preferably at least one ingredients selected from crospovidone, croscarmellose sodium, low- substituted hydroxypropyl cellulose, and crystalline cellulose and, although any of them may be used as a single, it is preferred to use as a mixture of two or more thereof. Amongst them, it is more preferred to use crospovidone and crystalline cellulose. When using crospovidone and crystalline cellulose, the ratio by weight of crospovidone and crystalline cellulose is 5 : 8 - 15 : 22, preferably 5 : 10 - 14 : 22, and more preferably 6 : 12 - 13 : 21.
  • the above disintegrating agent preferably has a mean particle size of 0.1 - 100 ⁇ m, more preferably 1 - 60 ⁇ m, and even more preferably 1 - 40 ⁇ m, in order to make a uniform dispersibility in the present composition and prevent a sandy feeling in oral cavity.
  • the desired mean particle size can be obtained by using a disintegrating agent micronized via a conventional method.
  • the saccharides are contained in 40 - 90 parts by weight, the inorganic substance is contained in 1 - 30 parts by weight, the disintegrating agent is contained in 5 - 40 parts by weight, and preferably the saccharides are contained in 50 - 80 parts by weight, the inorganic substance is contained in 2 - 15 parts by weight, the disintegrating agent is contained in 10 - 36 parts by weight.
  • the saccharides are contained in 62 - 78 parts by weight, the inorganic substance is contained in 3 - 8 parts by weight, the disintegrating agent is contained in 18 - 34 parts by weight.
  • the granulated particles can be prepared by a conventional method such as spray-drying method, fluid-bed granulation, agitation granulation and wet granulation (e.g. wet extrusion granulation), and also by the method described in WO 2007/029376. Such granulated particles are available, for example, as a commercially available F-MELT ® (FUJI CHEMICAL INDUSTRY CO., LTD.) .
  • the blending quantity of the granulated particles is generally about 10 - 60 % (w/w) , preferably about 20 - 40 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
  • the "glidant" used herein includes hydrous silicon dioxide, light anhydrous silicic acid, heavy anhydrous silicic acid and the like; preferably, light anhydrous silicic acid, or hydrous silicon dioxide; and more preferably light anhydrous silicic acid.
  • the glidant may comprise one or more of the above ingredients.
  • the blending quantity of the glidant is about 0.2 - 2 (w/w), preferably about 0.5 - 1.5 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
  • the "organic excipient" blended in the present solid formulation includes, for example, celluloses and starches.
  • the celluloses include, for example, crystalline cellulose, carboxymethylcellulose, ethylcellulose, carboxymethylethyl cellulose, carmellose sodium, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and the like.
  • it is crystalline cellulose or carboxymethylcellulose, and more preferably crystalline cellulose.
  • the starches include corn starch, rice starch, potato starch, flour starch, partial pregelatinized starch, hydroxypropyl starch, and the like.
  • the organic excipient may comprise one or more of the above ingredients.
  • crystalline cellulose and corn starch are used.
  • the blending quantity of the organic excipient is about 5 - 60 % (w/w) , preferably about 10 - 30 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
  • the present invention can include a variety of additives which are generally used in the preparation of tablets as long as the additives do not negatively affect its disintegrability and formability.
  • the additives include, for example, lubricants, sweeteners, flavoring substances, flavors, binders, and colorants.
  • the lubricant includes, for example, stearic acid, metal stearate (e.g. magnesium stearate, and calcium stearate) , stearyl fumarate sodium, talc, colloidal silica, sucrose fatty acid ester, hydrogenated oil, and polyethylene glycol. Amongst them, stearic acid and metal stearate are preferable, and magnesium stearate is more preferable.
  • the blending quantity of the lubricant is generally about 0.01 - 1 % (w/w) , preferably 0.1 - 0.6 %
  • the sweetener includes, for example, acesulfame potassium, aspartame, saccharin or a salt thereof, glycyrrhizinic acid or a salt thereof, stevia or a salt thereof, sucralose, and thaumatin.
  • the flavoring substance includes, for example, ascorbic acid or a salt thereof, glycine, sodium chloride, magnesium chloride, hydrochloric acid, diluted hydrochloric acid, citric acid or a salt thereof, anhydrous citric acid, L-glutamic acid or a salt thereof, succinic acid or a salt thereof, acetic acid, tartaric acid or a salt thereof, sodium hydrogen carbonate, fumaric acid or a salt thereof, malic acid or a salt thereof, glacial acetic acid, disodium inosinate, and honey.
  • ascorbic acid or a salt thereof glycine, sodium chloride, magnesium chloride, hydrochloric acid, diluted hydrochloric acid, citric acid or a salt thereof, anhydrous citric acid, L-glutamic acid or a salt thereof, succinic acid or a salt thereof, acetic acid, tartaric acid or a salt thereof, sodium hydrogen carbonate, fumaric acid or a salt thereof, malic acid or a salt
  • the flavor includes a favoring agent, for example, orange essence , orange oil, caramel, camphor, cinnamon oil, spearmint oil, strawberry essence, chocolate essence, cherry flavor, spruce oil, pine oil, mint oil, vanilla flavor, bitter essence, fruit flavor, peppermint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil, and rose oil.
  • a favoring agent for example, orange essence , orange oil, caramel, camphor, cinnamon oil, spearmint oil, strawberry essence, chocolate essence, cherry flavor, spruce oil, pine oil, mint oil, vanilla flavor, bitter essence, fruit flavor, peppermint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil, and rose oil.
  • the binder includes, for example, gum arabic, powdered acacia, gelatin, agar, dextrin, pullulan, povidone, and polyvinyl alcohol.
  • the colorant includes, for example, food colorant such as food dye Red No. 3, food dye Yellow No. 5, and food dye blue No. 1; yellow ferric oxide, red ferric oxide, brown iron oxide, black iron oxide, copper chlorophyll, sodium copper chlorophyllin, riboflavin, powdered green tea.
  • These additive ingredients can be generally used in any amount, and as a single or a mixture.
  • the exemplified process of the present orally disintegrating tablet includes a method comprising (1) weighing cilostazol and the other materials for formulation, (2) mixing the ingredients in a mixer such as a V-blender to prepare a mixed powder for tablet, and (3) directly compressing the powder .
  • a method of strongly mixing with an agitation granulation machine or a method of mixing and milling with a mill may be used.
  • a compaction-granulation method with a dry granulator; a wet granulation method with water, acetone, ethyl alcohol, propyl alcohol or a mixture thereof wherein optionally a binder may be dispersed or dissolved; or a method of preparing the mixed powder for tablet via separating it into two or more groups may be used.
  • a lubricant, a sweetener, a flavoring substance, a flavor, binder, a colorant, etc. may be optionally added thereto in preparing the mixed powder for tablet.
  • cilostazol and a glidant it is preferable to sufficiently mix cilostazol and a glidant firstly, and then to add an organic excipient, granulated particles, a sweetener and a lubricant thereto and sufficiently mix the mixture again.
  • the resulting mixed powder for tablet is compressed at a pressure of 200 kg - 600 kg/punch with for example a single tableting machine or a rotary tableting machine.
  • the pressure is lower than the above- mentioned range, the tablet hardness can be shortened and thus does not arrive at a sufficient hardness to be handled. While, when the pressure is higher than the above-mentioned range, the disintegration of the tablet can be disadvantageously delayed.
  • the compaction-formulation it is possible to use a conventional tableting method as well as an external lubricating compression.
  • the external lubricating compression enables the amount of a lubricant to be decreased, the disintegration rate to be accelerated, and the tablet hardness to be enhanced.
  • the shape of the orally disintegrating tablet it is possible to form any shape such as circular form, oval figure, globular shape, rod shape, and doughnut shape, as well as a lamination layer tablet, a dry-coated tablet, etc.
  • the tablet may be coated by a conventional coating method used in the field of formulation.
  • the orally disintegrating tablet can rapidly disintegrate in oral cavity with saliva, and hence it is possible to take a medicine smoothly.
  • the hardness which is measured with a tablet hardness tester is 30 N or more.
  • the disintegration time in oral cavity is generally within 90 seconds, preferably within 60 seconds, and more preferably within 40 seconds.
  • any additives defined herein such as inorganic substance, disintegrating agent, saccharide, glidant, organic excipient, starch, cellulose, additive, lubricant, sweetener, flavoring substance, flavor, binder and colorant which are expressed as a single or a plural form may include one kind of ingredient, plural kinds of ingredients and a mixture of plural kinds of ingredients.
  • cilostazol powder To 40 parts by weight of cilostazol powder were added 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 20 parts by weight of carmellose (NS-300, GOTOKU CHEMICAL COMPANY LTD.), 0.2 parts by weight of menthol (Takasago International
  • cilostazol powder 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 10 parts by weight of crystalline cellulose (Ceolus PH-IOl, Asahi Kasei Chemicals Corporation) , 10 parts by weight of corn starch (Nisshoku corn starch (XXl 6) W, Nihon Shokuhin Kako Co., Ltd.), 0.2 parts by weight of menthol (Takasago International Corporation), 0.2 parts by weight of aspartame (AJINOMOTO CO., INC.) and 0.4 parts by weight of magnesium stearate
  • cilostazol powder 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 20 parts by weight of rice starch (Micropearl, Shimada Chemical Company), 0.2 parts by weight of menthol (Takasago International Corporation), 0.2 parts by weight of aspartame (AJINOMOTO CO., INC.) and 0.4 parts by weight of magnesium stearate (TAIHEI CHEMICAL INDUSTRIAL CO. ,LTD.) .
  • Example 4 After mixing, the mixture was compression-molded with a rotary tableting machine (HT- APl 8SSI I type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch) to provide 250 mg tablets having a tablet hardness of 50 N.
  • a rotary tableting machine HT- APl 8SSI I type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch
  • cilostazol powder 40 parts by weight of cilostazol powder and 0.5 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed. And then, 33.7 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO., LTD.), 15 parts by weight of crystalline cellulose (Ceolus PH-101, Asahi Kasei Chemicals Corporation) , 10 parts by weight of corn starch (Nisshoku corn starch (XXl 6) W, Nihon Shokuhin Kako Co., Ltd.), 0.2 parts by weight of menthol (Takasago International
  • Example 7 The resulting mixture was compression-molded with a rotary tableting machine (HT-AP18SSII type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch) to provide 250 mg tablets having a tablet hardness of 50 N. [0047] (Example 7)
  • cilostazol powder 40 parts by weight of cilostazol powder and 0.5 parts by weight of hydrous silicon dioxide (Adsolider-102, Freund Corporation) were mixed. And then, 33.7 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 10 parts by weight of crystalline cellulose
  • 100 mg cilostazol tablets of Examples 1 to 7 and Reference Examples 1 and 2 were put in oral cavity and disintegrated on a tongue.
  • the time required for each tablet to be completely disintegrated was measured as an oral disintegration time and compared each other.
  • the pharmacopoeia disintegration time and the hardness of Examples 1 to 7 were also measured.
  • the hardness was measured with a Monsanto hardness tester (Kayagaki Irika Kougyo) , and the pharmacopoeia disintegration time was measured as time (sec.) required for each tablet to be completely disintegrated, according to the disintegration test in the Japanese pharmacopoeia 15th edition.
  • the disintegration test was carried out with water as a test solution and without a disk.
  • Example 4 In each process in Examples 1 to 7, especially, the pre-tableted compositions in Examples 4 to 7 which comprise a glidant had a better fluidity than those of Examples 1 to 3 and could be easily compression-molded.
  • the feeling test in oral cavity when administered was done. The feeling in oral cavity when administered was good in both the tablets, but the feeling of Example 7 was better than that of Example 4.
  • Example 8 40 parts by weight of cilostazol powder and 1.2 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed stirring in a high speed vertical granulator (VG-IO, POWREX CORPORATION, main paddle: 400 rpm, granulating paddle: 1500 rpm) for 15 minutes.
  • VG-IO high speed vertical granulator
  • XX16 XX16
  • Nihon Shokuhin Kako Co., Ltd. granulated particles
  • Example 9 40 parts by weight of cilostazol powder and 1.2 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed stirring in a high speed vertical granulator (FM-VG-120P, POWREX CORPORATION, main paddle: 240 rpm, granulating paddle: 1500 rpm) for 15 minutes.
  • FM-VG-120P high speed vertical granulator
  • the shape of the punch was circular form, the diameter thereof was 9 mm, and the tableting pressure was 400-500 kg.
  • the tablets prepared in Examples 8 and 9 were tested about some formulation properties, and the results were shown in Table 2.
  • the hardness was measured with a tablet hardness tester (Schleuniger) , and the pharmacopoeia disintegration time was measured as time (sec.) required for each tablet to be completely disintegrated, according to the disintegration test in the Japanese pharmacopoeia 15th edition.
  • the disintegration test was carried out with water as a test solution and without a disk.
  • the test was carried out with 6 tablets, the report was shown as an average thereof.
  • the tablets were orally administered to 6 healthy male adults, and -the time required for each tablet to be completely disintegrated in oral cavity only with saliva was measured. The results were shown below as an average thereof.
  • the dissolution test was done according to the dissolution test in the Japanese pharmacopoeia 15th edition, wherein the test solution was 900 ml of aqueous sodium lauryl sulfate (3 g in 1000 mL) , the method was paddle method, and the spinning rate was 50 rpm. The content of each sample was assayed by an ultraviolet-visible spectrophotometry (257 nm) .
  • Example 7 The tests were done with 3 tablets of Example 7, 6 tablets of Example 9 and 6 of the commercially available tablets containing 100 mg of cilostazol. The results were shown below as an average thereof.
  • the orally disintegrating tablet prepared according to the composition and the process shown in Example 9 had an equivalent dissolution profile with the commercially available tablets containing 100 mg of cilostazol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09714454A 2008-02-29 2009-02-26 Im mund zerfallende cilostazol-tablette Withdrawn EP2262487A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29
PCT/JP2009/054115 WO2009107864A2 (en) 2008-02-29 2009-02-26 An orally disintegrating tablet

Publications (1)

Publication Number Publication Date
EP2262487A2 true EP2262487A2 (de) 2010-12-22

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09714454A Withdrawn EP2262487A2 (de) 2008-02-29 2009-02-26 Im mund zerfallende cilostazol-tablette

Country Status (7)

Country Link
EP (1) EP2262487A2 (de)
JP (1) JP2011513194A (de)
AR (1) AR070530A1 (de)
CL (1) CL2009000452A1 (de)
PE (1) PE20091560A1 (de)
TW (1) TW200936184A (de)
WO (1) WO2009107864A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409294A1 (de) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tabletten mit cilostazolspezifischer teilchengrössenverteilung

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933205B (zh) 2010-04-28 2014-08-13 诺弗米克斯有限公司 西洛他唑共晶和组合物
ES2422657B1 (es) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Composición farmacéutica sólida de cilostazol
HK1206991A1 (en) 2012-07-20 2016-01-22 Otsuka Pharmaceutical Co., Ltd. Tablet having dry-ink film on surface thereof, and ink for inkjet printer
WO2015008825A1 (ja) 2013-07-19 2015-01-22 株式会社三和化学研究所 口腔内崩壊錠
WO2015046223A1 (ja) * 2013-09-27 2015-04-02 株式会社ダイセル 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP4551627B2 (ja) * 2003-02-28 2010-09-29 東和薬品株式会社 口腔内崩壊錠剤の製造方法
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
JP5074190B2 (ja) * 2005-09-02 2012-11-14 富士化学工業株式会社 口腔内速崩壊性錠剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009107864A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409294A1 (de) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tabletten mit cilostazolspezifischer teilchengrössenverteilung

Also Published As

Publication number Publication date
JP2011513194A (ja) 2011-04-28
WO2009107864A2 (en) 2009-09-03
TW200936184A (en) 2009-09-01
WO2009107864A3 (en) 2009-12-03
PE20091560A1 (es) 2009-10-30
CL2009000452A1 (es) 2010-03-26
AR070530A1 (es) 2010-04-14

Similar Documents

Publication Publication Date Title
JP3841804B2 (ja) 口腔内速崩壊性錠剤用の組成物
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
KR20130030306A (ko) 약학 조성물
JP2013224321A (ja) 口腔内崩壊錠剤
EP2465495A1 (de) Tablette mit schneller zersetzung im mund und zwei oder mehreren arten von partikeln
JP5870690B2 (ja) 口腔内崩壊錠及びその製造方法
JP7744908B2 (ja) ミロガバリンベシル酸塩を含有する口腔内崩壊錠
EP2262487A2 (de) Im mund zerfallende cilostazol-tablette
JP2000212094A (ja) 口腔用製剤
JP5074190B2 (ja) 口腔内速崩壊性錠剤
JP2025081466A (ja) 糖尿病治療用口腔内速崩壊錠
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
JP5275815B2 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP5978335B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017141299A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
KR100957731B1 (ko) 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
JP2005139086A (ja) 速崩壊製剤
TWI383809B (zh) 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
JP3899522B2 (ja) 苦味が低減されたプランルカスト水和物を含有する製剤
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP5714652B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP3637968B1 (ja) 胃内崩壊性錠剤
JP2021113237A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2018168185A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148961

Country of ref document: HK

17Q First examination report despatched

Effective date: 20140625

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150627

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1148961

Country of ref document: HK